Propanc Biopharma, Inc. (PPCB) News
Track canonical SquawkNews coverage tagged to PPCB, Propanc Biopharma, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
PPCB Highlights PRP Therapy
PPCB highlights PRP as a potential therapy for RAS-driven cancers
EQUITY | Aug 12, 2026, 12:31 PM UTC
H
Propanc Biopharma Reports Positive PRP Data
Propanc Biopharma reports positive PRP preclinical data
EQUITY | Aug 06, 2026, 12:31 PM UTC
L
Propanc Biopharma shares are trading higher after the company announced it has initiated a share repurchase program authorizing the company
Propanc Biopharma shares are trading higher after the company announced it has initiated a share repurchase program authorizing the company to repurchase a first tranche of up to $500,000 over the next 30-day period.
EQUITY | Jul 02, 2026, 03:14 PM UTC
L
Propanc Biopharma Initiates First Tranche Of $500K Stock Buyback Plan
Propanc Biopharma, Inc. (NASDAQ: PPCB ) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it
EQUITY | Jul 02, 2026, 12:31 PM UTC